AAPL   315.48 (-0.39%)
MSFT   178.55 (-1.66%)
FB   225.33 (-2.96%)
GOOGL   1,411.05 (-0.73%)
AMZN   2,386.19 (-1.47%)
CGC   19.39 (-3.10%)
BABA   200.23 (-0.74%)
GE   7.30 (+7.35%)
TSLA   803.61 (-1.86%)
AMD   50.50 (-5.06%)
ACB   15.30 (-1.99%)
DIS   121.56 (+0.50%)
BAC   25.55 (+5.23%)
AAPL   315.48 (-0.39%)
MSFT   178.55 (-1.66%)
FB   225.33 (-2.96%)
GOOGL   1,411.05 (-0.73%)
AMZN   2,386.19 (-1.47%)
CGC   19.39 (-3.10%)
BABA   200.23 (-0.74%)
GE   7.30 (+7.35%)
TSLA   803.61 (-1.86%)
AMD   50.50 (-5.06%)
ACB   15.30 (-1.99%)
DIS   121.56 (+0.50%)
BAC   25.55 (+5.23%)
AAPL   315.48 (-0.39%)
MSFT   178.55 (-1.66%)
FB   225.33 (-2.96%)
GOOGL   1,411.05 (-0.73%)
AMZN   2,386.19 (-1.47%)
CGC   19.39 (-3.10%)
BABA   200.23 (-0.74%)
GE   7.30 (+7.35%)
TSLA   803.61 (-1.86%)
AMD   50.50 (-5.06%)
ACB   15.30 (-1.99%)
DIS   121.56 (+0.50%)
BAC   25.55 (+5.23%)
AAPL   315.48 (-0.39%)
MSFT   178.55 (-1.66%)
FB   225.33 (-2.96%)
GOOGL   1,411.05 (-0.73%)
AMZN   2,386.19 (-1.47%)
CGC   19.39 (-3.10%)
BABA   200.23 (-0.74%)
GE   7.30 (+7.35%)
TSLA   803.61 (-1.86%)
AMD   50.50 (-5.06%)
ACB   15.30 (-1.99%)
DIS   121.56 (+0.50%)
BAC   25.55 (+5.23%)
Log in

NASDAQ:ATOSAtossa Genetics News Headlines

$2.20
-0.10 (-4.35 %)
(As of 05/27/2020 12:03 PM ET)
Add
Compare
Today's Range
$2.17
Now: $2.20
$2.27
50-Day Range
$1.04
MA: $1.88
$2.31
52-Week Range
$0.75
Now: $2.20
$3.25
Volume6,884 shs
Average Volume779,162 shs
Market Capitalization$20.26 million
P/E RatioN/A
Dividend YieldN/A
Beta2.59

Headlines

Atossa Genetics (NASDAQ ATOS) News Headlines

Source:
DateHeadline
Financial Analysis: Atossa Genetics (NASDAQ:ATOS) versus Regenicin (NASDAQ:RGIN)Financial Analysis: Atossa Genetics (NASDAQ:ATOS) versus Regenicin (NASDAQ:RGIN)
www.americanbankingnews.com - May 25 at 8:16 PM
Atossa Genetics (NASDAQ:ATOS) Earns Buy Rating from Analysts at Maxim GroupAtossa Genetics (NASDAQ:ATOS) Earns Buy Rating from Analysts at Maxim Group
www.americanbankingnews.com - May 24 at 6:04 AM
 Atossa Genetics Inc (NASDAQ:ATOS) Receives Consensus Recommendation of "Strong Buy" from Analysts Atossa Genetics Inc (NASDAQ:ATOS) Receives Consensus Recommendation of "Strong Buy" from Analysts
www.americanbankingnews.com - May 23 at 6:11 PM
Atossa Genetics Inc (NASDAQ:ATOS) Sees Significant Increase in Short InterestAtossa Genetics Inc (NASDAQ:ATOS) Sees Significant Increase in Short Interest
www.americanbankingnews.com - May 22 at 10:00 AM
Atossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory CultureAtossa Therapeutics Announces Successful In vitro Testing Results of COVID-19 Drug: AT-H201 Inhibits SARS-CoV-2 Infectivity of VERO Cells in Laboratory Culture
finance.yahoo.com - May 20 at 10:41 AM
Atossa Genetics (NASDAQ:ATOS) Releases  Earnings Results, Beats Expectations By $0.07 EPSAtossa Genetics (NASDAQ:ATOS) Releases Earnings Results, Beats Expectations By $0.07 EPS
www.americanbankingnews.com - May 14 at 9:12 PM
Atossa Therapeutics Announces First Quarter 2020 Financial Results and Provides Company Update on COVID-19 HOPE and Endoxifen ProgramsAtossa Therapeutics Announces First Quarter 2020 Financial Results and Provides Company Update on COVID-19 HOPE and Endoxifen Programs
finance.yahoo.com - May 13 at 1:52 PM
Atossa Therapeutics Receives FDA Feedback on Two Ongoing ProgramsAtossa Therapeutics Receives FDA Feedback on Two Ongoing Programs
finance.yahoo.com - May 7 at 12:24 PM
Atossa Therapeutics Announces Positive Interim Phase 2 Data from Endoxifen Breast Cancer TreatmentAtossa Therapeutics Announces Positive Interim Phase 2 Data from Endoxifen Breast Cancer Treatment
finance.yahoo.com - May 7 at 12:24 PM
Atossa Joins the Race to Find COVID-19 Treatment; Analyst Says ‘Buy’Atossa Joins the Race to Find COVID-19 Treatment; Analyst Says ‘Buy’
www.nasdaq.com - April 22 at 6:34 PM
Atossa Genetics Joins the Race to Find COVID-19 Treatment; Analyst Says ‘Buy’Atossa Genetics Joins the Race to Find COVID-19 Treatment; Analyst Says ‘Buy’
finance.yahoo.com - April 22 at 6:34 PM
BRIEF-Atossa Therapeutics Seeks Clinical Investigation Approval From FDA To Launch The Covid-19 Hope StudyBRIEF-Atossa Therapeutics Seeks Clinical Investigation Approval From FDA To Launch The Covid-19 Hope Study
www.reuters.com - April 21 at 1:49 AM
Atossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE StudyAtossa Therapeutics Seeks Clinical Investigation Approval from FDA to Launch the COVID-19 HOPE Study
finance.yahoo.com - April 20 at 3:48 PM
COVID-19 “Cease Fire” for the United States on April 23, 2020 and successful ‘Opening Up America Again’ initiative predictedCOVID-19 “Cease Fire” for the United States on April 23, 2020 and successful ‘Opening Up America Again’ initiative predicted
finance.yahoo.com - April 17 at 4:18 PM
BRIEF-Atossa Therapeutics Launches Covid-19 Hope Drug Development ProgramBRIEF-Atossa Therapeutics Launches Covid-19 Hope Drug Development Program
www.reuters.com - April 16 at 11:30 AM
Atossa Therapeutics Launches COVID-19 HOPE Drug Development ProgramAtossa Therapeutics Launches COVID-19 HOPE Drug Development Program
finance.yahoo.com - April 16 at 11:30 AM
Atossa Therapeutics Announces Clinical ProgressAtossa Therapeutics Announces Clinical Progress
finance.yahoo.com - April 2 at 5:05 PM
New COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus PatientsNew COVID-19 HOPE Clinical Trial Recommendations Introduced Today May Reduce or Eliminate Mechanical Ventilation for Coronavirus Patients
finance.yahoo.com - March 30 at 8:38 PM
BRIEF-Atossa Therapeutics Announces Fourth Quarter And Year End 2019 Financial Results And Provides Company UpdateBRIEF-Atossa Therapeutics Announces Fourth Quarter And Year End 2019 Financial Results And Provides Company Update
www.reuters.com - March 26 at 11:20 PM
Atossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company UpdateAtossa Therapeutics Announces Fourth Quarter and Year End 2019 Financial Results and Provides Company Update
finance.yahoo.com - March 26 at 8:19 AM
Atossa Therapeutics Announces Upcoming Meeting with FDAAtossa Therapeutics Announces Upcoming Meeting with FDA
finance.yahoo.com - March 13 at 9:03 AM
Atossa Therapeutics, Inc. Files for Swedish Regulatory Approval to Initiate a Phase 2 Study of Oral Endoxifen to Reduce Mammographic Breast DensityAtossa Therapeutics, Inc. Files for Swedish Regulatory Approval to Initiate a Phase 2 Study of Oral Endoxifen to Reduce Mammographic Breast Density
finance.yahoo.com - March 2 at 8:40 AM
Estrogen Receptor Beta Market: Dynamics, Segments, Size and Demand Analysis during 2020-2025Estrogen Receptor Beta Market: Dynamics, Segments, Size and Demand Analysis during 2020-2025
www.marketwatch.com - February 25 at 1:47 PM
Estrogen Receptor Beta Market Inclinations & Development Status Highlighted During Forecast Period 2020-2025Estrogen Receptor Beta Market Inclinations & Development Status Highlighted During Forecast Period 2020-2025
www.marketwatch.com - February 25 at 1:47 PM
Atossa Genetics Announces Third Quarter 2017 Financial Results And Provides Company UpdateAtossa Genetics Announces Third Quarter 2017 Financial Results And Provides Company Update
www.bloomberg.com - February 20 at 7:20 PM
Atossa Therapeutics, Inc. to Present at the 22nd Annual BIO CEO & Investor ConferenceAtossa Therapeutics, Inc. to Present at the 22nd Annual BIO CEO & Investor Conference
finance.yahoo.com - February 5 at 9:09 AM
Interview with Atossa Therapeutics Kyle Guse On World Cancer Day "Transforming Breast Cancer Treatment"Interview with Atossa Therapeutics' Kyle Guse On World Cancer Day "Transforming Breast Cancer Treatment"
finance.yahoo.com - February 4 at 6:53 PM
Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2020Atossa Therapeutics President and CEO Dr. Steven C. Quay Issues Annual Letter to Shareholders Highlighting Key Accomplishments and Strategy for 2020
finance.yahoo.com - January 22 at 5:40 PM
Atossa Genetics Announces Corporate Name Change to Atossa Therapeutics, Inc.Atossa Genetics Announces Corporate Name Change to Atossa Therapeutics, Inc.
www.globenewswire.com - January 6 at 1:34 PM
Atossa Genetics Announces Corporate Name Change to Atossa Therapeutics, Inc.Atossa Genetics Announces Corporate Name Change to Atossa Therapeutics, Inc.
finance.yahoo.com - January 6 at 1:34 PM
Atossa launches Phase 2 study for oral EndoxifenAtossa launches Phase 2 study for oral Endoxifen
seekingalpha.com - December 19 at 1:02 PM
Atossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in WomenAtossa Genetics Announces Phase 2 Study Contract for Oral Endoxifen to Reduce Mammographic Breast Density in Women
finance.yahoo.com - December 19 at 1:02 PM
Is Atossa Genetics (NASDAQ:ATOS) In A Good Position To Deliver On Growth Plans?Is Atossa Genetics (NASDAQ:ATOS) In A Good Position To Deliver On Growth Plans?
finance.yahoo.com - December 16 at 1:58 PM
Atossa Genetics to Present at the LD Micro 12th Annual Main Event on December 10, 2019Atossa Genetics to Present at the LD Micro 12th Annual Main Event on December 10, 2019
finance.yahoo.com - December 5 at 1:04 PM
Atossa Genetics Announces Third Quarter 2019 Financial Results and Provides Company UpdateAtossa Genetics Announces Third Quarter 2019 Financial Results and Provides Company Update
finance.yahoo.com - November 13 at 12:23 PM
Atossa Genetics to Present on October 29th at the 5th Annual Dawson James Small Cap Growth ConferenceAtossa Genetics to Present on October 29th at the 5th Annual Dawson James Small Cap Growth Conference
finance.yahoo.com - October 23 at 1:06 PM
Atossa up 10% premarket on IRB sign-off of mid-stage study of microcatheterAtossa up 10% premarket on IRB sign-off of mid-stage study of microcatheter
seekingalpha.com - October 16 at 1:34 PM
Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal TechnologyAtossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology
finance.yahoo.com - October 16 at 1:34 PM
Atossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal TechnologyAtossa Genetics Receives IRB Approval for Phase 2 Breast Cancer Study Using Intraductal Technology
www.globenewswire.com - October 16 at 8:33 AM
Interview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over GynecomastiaInterview With Atossa Genetics Founder & CEO Steven Quay MD, Ph.D. Over Gynecomastia
finance.yahoo.com - October 15 at 1:26 PM
BRIEF-Atossa Genetics Announces Preliminary Results From Phase 1 Study Of Modified-Release Tablet Oral EndoxifenBRIEF-Atossa Genetics Announces Preliminary Results From Phase 1 Study Of Modified-Release Tablet Oral Endoxifen
www.msn.com - September 30 at 10:24 PM
Atossa Genetics reports positive Endoxifen dataAtossa Genetics reports positive Endoxifen data
seekingalpha.com - September 30 at 5:23 PM
Atossa Genetics Announces Preliminary Results from Phase 1 Study of Modified-Release Tablet Oral EndoxifenAtossa Genetics Announces Preliminary Results from Phase 1 Study of Modified-Release Tablet Oral Endoxifen
finance.yahoo.com - September 30 at 5:23 PM
Global Molecular Biomarkers Market Industry Analysis, Product Capacity, Growth Demand and Future Forecast Period Till 2022Global Molecular Biomarkers Market Industry Analysis, Product Capacity, Growth Demand and Future Forecast Period Till 2022
www.marketwatch.com - September 21 at 1:27 AM
Atossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment ConferenceAtossa Genetics to Present September 10 at the 21st Annual Rodman and Renshaw Global Investment Conference
finance.yahoo.com - September 6 at 12:47 PM
Atossa Genetics EPS misses by $0.32Atossa Genetics EPS misses by $0.32
seekingalpha.com - August 13 at 11:56 PM
Atossa Genetics Announces Second Quarter 2019 Financial Results and Provides Company UpdateAtossa Genetics Announces Second Quarter 2019 Financial Results and Provides Company Update
finance.yahoo.com - August 13 at 11:56 PM
Atossa Genetics CEO Steven Quay Gives Tedx Talk At University of Washington Regarding the the Relationship of Dense Breast Tissue and Breast Cancer RiskAtossa Genetics CEO Steven Quay Gives Tedx Talk At University of Washington Regarding the the Relationship of Dense Breast Tissue and Breast Cancer Risk
finance.yahoo.com - July 30 at 8:40 AM
Atossa Genetics Provides Information on FDA Expanded Access Policy and RequestsAtossa Genetics Provides Information on FDA Expanded Access Policy and Requests
finance.yahoo.com - July 17 at 6:49 PM
Atossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial InitiatedAtossa Genetics Announces New Proprietary Modified-Release Oral Endoxifen Tablet; Phase 1 Clinical Trial Initiated
finance.yahoo.com - July 11 at 6:30 PM
This page was last updated on 5/27/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.